StockWatch
·
Biotechnology: Pharmaceutical Preparations
Clinical TrialNov 20, 2026, 04:12 PM

Acrivon Therapeutics Presents Promising ACR-2316 Clinical Trial Data

AI Summary

Acrivon Therapeutics, Inc. presented late-breaker data from its ACR-2316 Phase 1/2 trial at the 38th EORTC-NCI-AACR Symposium. The presentation highlighted safety, dose optimization, and early clinical results for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor designed using the company's AP3 platform. Promising clinical activity was observed at doses of 120 mg and 160 mg, with durable benefits noted in lung cancer patients. The company is advancing two optimized doses into a randomized expansion phase.

Key Highlights

  • Acrivon Therapeutics presented Phase 1/2 data for ACR-2316, a WEE1/PKMYT1 inhibitor, at the 38th EORTC-NCI-AACR Symposium.
  • ACR-2316 demonstrated a favorable safety profile, with predominantly transient, asymptomatic neutropenia.
  • Durable single-agent activity was observed, including a confirmed Complete Response in a SqNSCLC patient on study for over 65 weeks.
  • 5 out of 7 lung cancer patients experienced clinical benefit at doses ≥120 mg.
  • Two optimized doses (120 mg and 160 mg) are advancing into a randomized expansion phase (NCT06667141).
  • The AP3 platform was used to design ACR-2316 for dual WEE1/PKMYT1 inhibition and activation of CDK1, CDK2, and PLK1.